Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Minority Interest (2021 - 2025)

Historic Minority Interest for Rani Therapeutics Holdings (RANI) over the last 5 years, with Q3 2025 value amounting to -$4.1 million.

  • Rani Therapeutics Holdings' Minority Interest fell 25491.53% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.1 million, marking a year-over-year decrease of 25491.53%. This contributed to the annual value of $1.5 million for FY2024, which is 8806.55% down from last year.
  • Latest data reveals that Rani Therapeutics Holdings reported Minority Interest of -$4.1 million as of Q3 2025, which was down 25491.53% from -$3.6 million recorded in Q2 2025.
  • Rani Therapeutics Holdings' Minority Interest's 5-year high stood at $80.3 million during Q3 2021, with a 5-year trough of -$4.1 million in Q3 2025.
  • Over the past 5 years, Rani Therapeutics Holdings' median Minority Interest value was $17.3 million (recorded in 2023), while the average stood at $25.5 million.
  • As far as peak fluctuations go, Rani Therapeutics Holdings' Minority Interest crashed by 4472.01% in 2022, and later crashed by 25491.53% in 2025.
  • Rani Therapeutics Holdings' Minority Interest (Quarter) stood at $74.2 million in 2021, then plummeted by 49.9% to $37.1 million in 2022, then plummeted by 66.14% to $12.6 million in 2023, then tumbled by 88.07% to $1.5 million in 2024, then tumbled by 374.02% to -$4.1 million in 2025.
  • Its Minority Interest stands at -$4.1 million for Q3 2025, versus -$3.6 million for Q2 2025 and -$2.3 million for Q1 2025.